Dr. Perl on Genetic Testing and Targeted Therapies in AML
Alexander E. Perl, MD, MS, associate professor, medicine, the Hospital of the University of Pennsylvania, discusses why genetic testing is important for determining targeted therapies for patients with acute myeloid leukemia.
Dr. Perl on Challenges of Implementing Immunotherapy in AML
Alexander E. Perl, MD, MS, discusses the challenges of using immunotherapy with antibody-drug conjugates, bispecific T-cell engagers, and CAR T-cell therapies in acute myeloid leukemia.
Dr. Perl on Choosing the Optimal Therapy in AML
Alexander E. Perl, MD, MS, discusses how to assess what therapy is best for patients with acute myeloid leukemia.
Selecting the Appropriate CAR T-Cell Therapy for Patients with R/R LBCL
Is There a Potential Role for Rapcabtagene Autoleucel in R/R LBCL?
PD-1 Inhibitor Combinations, Alternative Therapeutic Approaches Are Moving the Needle in NSCLC
Better Understanding of Biomarkers Can Inform Immunotherapy Treatment in SCLC
2 Clarke Drive Cranbury, NJ 08512